Maxwell Skor
Stock Analyst at Morgan Stanley
(2.46)
# 2,142
Out of 5,182 analysts
7
Total ratings
50%
Success rate
19.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Initiates: Overweight | $115 | $53.25 | +115.96% | 1 | Jan 9, 2026 | |
| INSM Insmed | Maintains: Equal-Weight | $126 → $144 | $133.26 | +8.06% | 1 | Aug 21, 2025 | |
| ASND Ascendis Pharma | Assumes: Overweight | $250 | $220.93 | +13.16% | 1 | Jul 3, 2025 | |
| SANA Sana Biotechnology | Assumes: Overweight | $12 | $3.27 | +266.97% | 1 | Jul 3, 2025 | |
| TCRX TScan Therapeutics | Assumes: Overweight | $10 | $1.22 | +719.67% | 1 | Mar 14, 2025 | |
| IVVD Invivyd | Maintains: Overweight | $9.5 → $3.55 | $1.52 | +133.55% | 2 | Nov 20, 2024 |
Monopar Therapeutics
Jan 9, 2026
Initiates: Overweight
Price Target: $115
Current: $53.25
Upside: +115.96%
Insmed
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $126 → $144
Current: $133.26
Upside: +8.06%
Ascendis Pharma
Jul 3, 2025
Assumes: Overweight
Price Target: $250
Current: $220.93
Upside: +13.16%
Sana Biotechnology
Jul 3, 2025
Assumes: Overweight
Price Target: $12
Current: $3.27
Upside: +266.97%
TScan Therapeutics
Mar 14, 2025
Assumes: Overweight
Price Target: $10
Current: $1.22
Upside: +719.67%
Invivyd
Nov 20, 2024
Maintains: Overweight
Price Target: $9.5 → $3.55
Current: $1.52
Upside: +133.55%